X4 Pharmaceuticals, Inc
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|
For the quarterly period ended September 30, 2025
or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|
For the transition period from __________ to __________
Commission File Number:001-38295
(Exact name of registrant as specified in its charter)
| Delaware(State or other jurisdiction ofincorporation or organization) | 27-3181608(I.R.S. EmployerIdentification No.) |
|---|---|
| 61 North Beacon Street, 4th FloorBoston, Massachusetts(Address of principal executive offices) | 02134(Zip Code) |
(857)529-8300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.001 per share | XFOR | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
|---|---|---|---|
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☐ | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐ No ☒
As of October 31, 2025, the registrant had 87,436,688 shares of common stock, $0.001 par value per share, outstanding.
| X4 PHARMACEUTICALS INC.TABLE OF CONTENTS | ||
|---|---|---|
| PART I: FINANCIAL INFORMATION | ||
| ITEM 1: FINANCIAL STATEMENTS | 3 | |
| Condensed Consolidated Balance Sheets (unaudited) | 3 | |
| Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) | 4 | |
| Condensed Consolidated Statements Stockholders’ Equity (unaudited) | 5 | |
| Condensed Consolidated Statements of Cash Flows (unaudited) | 7 | |
| Notes to Condensed Consolidated Financial Statements | 8 | |
| ITEM 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations | 27 | |
| ITEM 3: Quantitative and Qualitative Disclosures About Market Risk | 34 | |
| ITEM 4: Controls and Procedures | 34 | |
| PART II: OTHER INFORMATION | ||
| ITEM 1: Legal Proceedings | 35 | |
| ITEM 1A: Risk Factors | 35 | |
| ITEM 2: Unregistered Sales of Equity Securities and Use of Proceeds | 35 | |
| ITEM 3: Defaults upon Senior Securities | 35 | |
| ITEM 4: Mine Safety Disclosures | 35 | |
| ITEM 5: Other Information | 35 | |
| ITEM 6: Exhibits | 37 | |
| Signatures | 39 | |
EXPLANATORY NOTE
On April 28, 2025, X4 Pharmaceuticals, Inc. (the “Company”), effected a 1-for-30 reverse stock split of its common stock (the “Reverse Stock Split”). Unless otherwise noted, all references to common stock share and per share amounts in this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the Reverse Stock Split.
See Note 13 of the condensed consolidated financial statements for a description of the Reverse Stock Split.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.